A Study in Subjects With Retinitis Pigmentosa

• Status: Recruiting
• Trial end date: 2022-12-31
• Target enrollment: 0
• Participant gender: All

Summary

An open-label Phase II clinical trial, 8 (eight) subjects with retinitis pigmentosa due to rhodopsin mutations (including P23H) will be identified and treated with serial intravitreal injections of ADX-2191 in the worse seeing eye. Ocular structure and function will be evaluated.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Aldeyra Therapeutics, Inc.

Criteria

Inclusion Criteria:

1. Up to 8 adult patients age 18 or older

2. Diagnosis of retinitis pigmentosa due to rhodopsin gene mutation, including P23H

3. Impairment on Visual Field as determined by perimetry

Exclusion Criteria:

1. Age < 18 years

2. Pregnant

3. Previous inflammatory/infectious events involving the eyes